Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Healthy male aged 18 to 45 years with a BMI between 18 and 30 kg/m2, (inclusive).~Exclusion Criteria:~* Standard exclusion criterion for Phase 1 clinical trial in healthy subjects.~* History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate~* History or presence of GI, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs as judged by Investigator.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Single ascending dose (Type: PLACEBO_COMPARATOR): Single dose of SUVN-G3031or placebo in healthy male subjects
- Multiple ascending dose (Type: PLACEBO_COMPARATOR): Multiple doses of SUVN-G3031 or placebo in healthy male subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).